Gelonghui, on October 28th, Hunan Hansen Pharmaceutical (002412.SZ) released its third quarter report for 2024, achieving a revenue of 0.694 billion yuan in the first three quarters, a year-on-year increase of 1.44%; net income attributable to the shareholders of the listed company was 0.131 billion yuan, a year-on-year increase of 19.15%; net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 0.123 billion yuan, a year-on-year increase of 19.14%; and the basic earnings per share was 0.2598 yuan.
汉森制药(002412.SZ)：前三季度净利润1.31亿元 同比增长19.15%
hunan hansen pharmaceutical (002412.SZ): net income of 0.131 billion yuan in the first three quarters, a year-on-year increase of 19.15%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated